Thera-SAbDab

DOCARAVIMAB

>   Structural Summary
TherapeuticDocaravimab
TargetRabies Virus Strain ERA GP Ectodomain Epitope G-III
Heavy ChainQVQLKESGPGLLAPSQSLSITCTVSGFSLTGHGVNWVRQPPGKGLEWLGIIWADGTTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTASYYCAREGDISGYYFDYWGQGTTLTVSS
Light ChainDVQMTQTTSSLSASLGDRVTITCRPSQDINNYLSWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDFATYFCQQGNTLPPTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb (Mouse)
IsotypeG2b
Highest Clinical Trial (June '19)Phase-I
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year RecommendedNone
Companies InvolvedCandila Healthcare
Conditions Approvedna
Conditions ActiveRabies post-exposure
Conditions Discontinuedna
NotesMouse antibody

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]